DE69233643D1 - Verwendung von Antizytokin-enthaltenden pharmazeutische Zusammensetzungen zur Therapie von multipler Sklerose - Google Patents

Verwendung von Antizytokin-enthaltenden pharmazeutische Zusammensetzungen zur Therapie von multipler Sklerose

Info

Publication number
DE69233643D1
DE69233643D1 DE69233643T DE69233643T DE69233643D1 DE 69233643 D1 DE69233643 D1 DE 69233643D1 DE 69233643 T DE69233643 T DE 69233643T DE 69233643 T DE69233643 T DE 69233643T DE 69233643 D1 DE69233643 D1 DE 69233643D1
Authority
DE
Germany
Prior art keywords
anticytokin
therapy
pharmaceutical compositions
multiple sclerosis
containing pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233643T
Other languages
English (en)
Other versions
DE69233643T2 (de
Inventor
David Wallach
Dan Aderka
Hartmut Engelmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11062415&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69233643(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE69233643D1 publication Critical patent/DE69233643D1/de
Application granted granted Critical
Publication of DE69233643T2 publication Critical patent/DE69233643T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69233643T 1991-05-07 1992-05-07 Verwendung von Antizytokin-enthaltenden pharmazeutischen Zusammensetzungen zur Therapie von multipler Sklerose Expired - Lifetime DE69233643T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL9807891 1991-05-07
IL98078A IL98078A0 (en) 1991-05-07 1991-05-07 Pharmaceutical compositions comprising an anticytokyne

Publications (2)

Publication Number Publication Date
DE69233643D1 true DE69233643D1 (de) 2006-09-14
DE69233643T2 DE69233643T2 (de) 2007-07-26

Family

ID=11062415

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69229975T Expired - Lifetime DE69229975T2 (de) 1991-05-07 1992-05-07 Pharmazeutische Zusammensetzungen, die ein Anticytokin enthalten
DE69233643T Expired - Lifetime DE69233643T2 (de) 1991-05-07 1992-05-07 Verwendung von Antizytokin-enthaltenden pharmazeutischen Zusammensetzungen zur Therapie von multipler Sklerose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69229975T Expired - Lifetime DE69229975T2 (de) 1991-05-07 1992-05-07 Pharmazeutische Zusammensetzungen, die ein Anticytokin enthalten

Country Status (12)

Country Link
EP (2) EP0512528B1 (de)
JP (1) JP3320774B2 (de)
AT (2) ATE334695T1 (de)
AU (1) AU1609492A (de)
CA (1) CA2068027C (de)
DE (2) DE69229975T2 (de)
DK (2) DK0880970T3 (de)
ES (2) ES2137935T3 (de)
GR (1) GR3031805T3 (de)
IL (1) IL98078A0 (de)
PT (1) PT880970E (de)
ZA (1) ZA923310B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
EP0393438B1 (de) * 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
ATE196849T1 (de) * 1993-07-30 2000-10-15 Kennedy Inst Of Rheumatology Verfahren zur behandlung von multiplesklerose
AU3111995A (en) * 1994-07-22 1996-02-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
ATE212231T1 (de) 1995-07-14 2002-02-15 Applied Research Systems Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
EP0942740B1 (de) 1996-12-06 2003-08-27 Amgen Inc., Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
PT1471974E (pt) 2002-02-06 2007-10-12 Ares Trading Sa Factor de necrose tumural combinado com interferão em doenças desmielinizantes
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SG10201604093XA (en) 2010-01-15 2016-07-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
SG11201607881SA (en) 2014-03-31 2016-10-28 Kirin Amgen Inc Methods of treating nail and scalp psoriasis
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
EP0393438B1 (de) * 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
ATE119942T1 (de) * 1989-05-18 1995-04-15 Yeda Res & Dev Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
ATE128184T1 (de) * 1989-12-13 1995-10-15 Yeda Res & Dev Expression des rekombinanten tumor-nekrosisfaktor-bindungsproteins i (tbp-i).
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
RU2166955C2 (ru) * 1991-01-18 2001-05-20 Эмген Инк. Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0880970B1 (de) 2006-08-02
PT880970E (pt) 2006-12-29
JPH05170661A (ja) 1993-07-09
DE69229975T2 (de) 2000-05-11
EP0512528A3 (en) 1993-07-21
ATE184488T1 (de) 1999-10-15
JP3320774B2 (ja) 2002-09-03
ATE334695T1 (de) 2006-08-15
DK0880970T3 (da) 2006-11-20
IL98078A0 (en) 1992-06-21
ZA923310B (en) 1993-01-27
CA2068027C (en) 2003-09-23
GR3031805T3 (en) 2000-02-29
DK0512528T3 (da) 1999-12-20
ES2137935T3 (es) 2000-01-01
DE69233643T2 (de) 2007-07-26
EP0880970A1 (de) 1998-12-02
EP0512528A2 (de) 1992-11-11
AU1609492A (en) 1992-11-12
CA2068027A1 (en) 1992-11-08
EP0512528B1 (de) 1999-09-15
DE69229975D1 (de) 1999-10-21
ES2270479T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
DE69233643D1 (de) Verwendung von Antizytokin-enthaltenden pharmazeutische Zusammensetzungen zur Therapie von multipler Sklerose
ATE535255T1 (de) Anti-tnf antikörper und methotrexat zur gleichzeitigen behandlung von autoimmunkrankheiten
EP0787802A3 (de)
NO943617L (no) Fusjonsproteiner omfattende tumornekrosefaktor-reseptor
FI852626A0 (fi) Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
FI900808A0 (fi) Humant mannos bindande protein.
DE69233011D1 (de) Rekombinante antikörper zur humanen therapie
ATE54826T1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
NO931413D0 (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
ATE428438T1 (de) Tcf-ii enthaltende medizinische zusammensetzung
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
DE69017825D1 (de) Heilverfahren von Lebererkrankungen mit Verwendung von Pyrrol-Chinolin-Chinone-Triester und neue Pyrrol-Chinolin-Chinone-Triester.
DK0606869T3 (da) Promotorsekvens for p55-receptoren for tumornekrosefaktor
DE69118847D1 (de) Verwendung von Heptastigmin zur Behandlung der zerebralen Ictus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 880970

Country of ref document: EP